# The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland

> **NCT06889948** · PHASE2 · RECRUITING · sponsor: **Helsinki University Central Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Kidney Failure
- Paraproteinemias
- Glomerulonephritis

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT06889948
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-19
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889948, "The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06889948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*